Related Experiment Video
Updated: Jul 12, 2026
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
Published on: April 9, 2019
[Omission factors in detecting early stage prostate cancer by TRUS needle biopsy]
Shi-Wei Zhang1, Hong-Qian Guo, Wei-Dong Gan
1Department of Urology, Nanjing Drum Tower Hospital, Nanjing University Medical College, Nanjing, Jiangsu 210008, China. zswzy456@sohu.com
Objective:
To analyze and reduce the omission factors in detecting early stage prostate cancer by TRUS needle biopsy, and to improve the diagnosis of the disease.
Methods:
A total of 80 benign prostatic hyperplasia patients suspected of prostatic carcinoma underwent TRUS sextant biopsies. The pathological results being negative, the patients received transurethral resection of the prostate (TURP).
Results:
After TURP, 25 cases were pathologically diagnosed as prostate cancer, with an omission rate of 31.25% (25/80). Of the diagnosed cancer patients, 10 were treated by radical perineum prostatectomy, 8 by surgical castration, and 7 by medical castration.
Conclusion:
Some tumors may fail to be detected by TRUS needle biopsy. Serial or multi-core needle biopsies can decrease the omission rate in the diagnosis of organ confined cancer.
